Liver Disease Therapeutics Market Size & Growth Forecast 2027–2036, By Segments (Disease, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Liver Disease Therapeutics Market size was around USD 23.6 billion in 2026 and is slated to grow at a 7.51% CAGR from 2027 to 2036, attaining USD 48.69 billion by 2036. The industry revenue for 2027 is estimated at USD 25.09 billion.
Get more details on this report
Request Free Sample ReportLiver Disease Therapeutics Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 42.26% market share in 2026, supported by established treatment infrastructure, higher diagnosis rates, strong payer coverage, and routine use of advanced liver therapies.
- Asia Pacific is projected to grow at a 6.55% CAGR as improving diagnosis, expanding healthcare capacity, broader reimbursement, and greater treatment access increase demand for liver disease therapies.
Segment Momentum
- Antiviral drugs held a 42.23% share in 2026 because they are central to hepatitis treatment, benefiting from established clinical pathways, routine prescribing practices, and consistent therapeutic demand.
- NAFLD is growing fastest as clinical focus shifts toward metabolic and lifestyle-related liver disorders, with improving diagnosis and significant unmet therapeutic need driving earlier intervention and treatment expansion.
Market Expansion Drivers
- Rising prevalence of NAFLD, hepatitis, and ALD driving demand for advanced liver treatments.
- Advancements in antiviral and mRNA-based therapies improving treatment efficacy and outcomes.
- Increasing obesity and diabetes rates accelerating metabolic liver disease treatment demand.
Leading Market Participants
- Major players in the liver disease therapeutics market include Gilead Sciences, Inc. (United States), AbbVie Inc. (United States), Bristol-Myers Squibb Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Johnson & Johnson (United States), Merck & Co., Inc. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi S.A. (France).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 23.6 billion
- 2027 Estimated Market Size: USD 25.09 billion.
- Projected Market Size: USD 48.69 billion by 2036
- Growth Forecast: 7.51% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hepatitis (Disease) | Antiviral Drugs (Product)
- Emerging Opportunity Segment: Non-alcoholic Fatty Liver Disease (NAFLD) (Disease) | Targeted Therapy (Product)
Market Growth Drivers and Industry Trends
Rising prevalence of NAFLD, hepatitis, and ALD driving demand for advanced liver treatments
Increasing prevalence of NAFLD, hepatitis, and ALD is creating a broader treatment requirement across patients with different forms of liver disease, which will propel the liver disease therapeutics market growth by strengthening demand for therapies that address persistent and complex hepatic conditions. The expanding disease burden also supports greater attention to effective treatment options across healthcare settings.
Advancements in antiviral and mRNA-based therapies improving treatment efficacy and outcomes
Technological progress in antiviral and mRNA-based approaches is improving the therapeutic possibilities available for liver diseases, supporting the liver disease therapeutics market growth through more targeted and potentially effective treatment strategies. These advances can expand treatment options while improving the ability to address disease mechanisms and patient outcomes more effectively.
Increasing obesity and diabetes rates accelerating metabolic liver disease treatment demand
Rising obesity and diabetes are contributing to greater demand for therapies addressing metabolic liver conditions, making these underlying health trends an important source of demand for the liver disease therapeutics market. As metabolic disorders become more closely associated with liver complications, healthcare providers require treatment approaches capable of addressing the resulting therapeutic needs.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of NAFLD, hepatitis, and ALD driving demand for advanced liver treatments | 2.30% | High | North America, Asia Pacific | High | Near Term |
| Advancements in antiviral and mRNA-based therapies improving treatment efficacy and outcomes | 2.00% | High | North America, Europe | High | Near Term |
| Increasing obesity and diabetes rates accelerating metabolic liver disease treatment demand | 1.70% | High | Global | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the liver disease therapeutics market with a 42.26% share in 2026, reflecting advanced healthcare infrastructure, strong diagnostic capabilities, and substantial demand for treatments targeting chronic and progressive liver conditions. High awareness of liver health, established specialist care networks, and access to advanced therapeutic approaches support sustained treatment adoption. The region also benefits from strong clinical research activity and healthcare systems that increasingly emphasize early diagnosis and disease management. Growing attention to metabolic disorders, alcohol-related liver damage, and other underlying risk factors further reinforces demand for effective therapeutic interventions.
Asia Pacific (Fastest-Growing Region)
The Asia Pacific liver disease therapeutics market is experiencing the fastest growth as healthcare systems expand their capacity to diagnose and manage liver disorders. Increasing awareness of chronic liver conditions, broader access to specialist services, and improvements in diagnostic infrastructure are supporting earlier treatment initiation. The region’s large patient population and rising burden of conditions associated with metabolic health and infectious diseases create a substantial treatment need. Expanding healthcare expenditure, improved availability of advanced medicines, and greater emphasis on disease screening are also strengthening the adoption environment across major regional markets.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Hepatology FocusGermany emphasizes evidence-based treatment pathways and specialist care networks for chronic liver diseases. The country is increasing attention on therapies addressing fatty liver disease and fibrosis, creating demand for treatments that align with precision medicine and long-term disease management strategies.
France 🇫🇷
Integrated Chronic CareFrance is prioritizing coordinated management of chronic liver diseases through specialist care and preventive health programs. The French market increasingly favors therapies that reduce long-term disease burden and support treatment of advanced liver fibrosis and cirrhosis.
Italy 🇮🇹
Hepatitis Treatment ModernizationItaly continues to modernize liver disease management through expanded access to therapies for viral hepatitis and chronic liver disorders. Italian healthcare systems are placing greater emphasis on early diagnosis and treatment pathways that prevent progression to severe liver complications.
Japan 🇯🇵
Aging Liver Care DemandJapan's aging population is driving demand for therapies that manage chronic liver conditions and associated complications. Japanese healthcare providers are focusing on improving patient outcomes through earlier intervention and wider use of treatments addressing viral hepatitis and metabolic liver diseases.
South Korea 🇰🇷
Metabolic Disease ManagementSouth Korea is strengthening its focus on liver diseases linked to obesity and metabolic disorders. The country is supporting adoption of innovative therapeutics and improved screening practices, creating opportunities for treatments that address increasing rates of non-alcoholic fatty liver disease.
United States 🇺🇸
Advanced Therapy AdoptionThe U.S. liver disease therapeutics market is shaped by growing use of targeted therapies and expanding clinical activity in metabolic and viral liver disorders. Healthcare providers in the U.S. are prioritizing earlier diagnosis and integrating novel treatment approaches for conditions such as NASH and cirrhosis.
Segment Leadership and Growth Trends
Liver Disease Therapeutics Market Share (%), by Disease, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDisease Segment Analysis: Hepatitis (Largest Segment) vs Non-alcoholic Fatty Liver Disease (NAFLD) (Fastest-Growing Segment)
Hepatitis dominated the liver disease therapeutics market with a 42.87% share in 2026, reflecting the substantial demand for therapies addressing viral liver infections and their associated complications. Continued emphasis on diagnosis, disease management, and prevention of progression to advanced liver conditions supports sustained therapeutic demand. The availability of established treatment approaches and ongoing improvements in clinical management further reinforce hepatitis as a major disease category within the market.
Non-alcoholic fatty liver disease (NAFLD) is advancing rapidly as changing lifestyles, metabolic health concerns, and increasing clinical recognition of liver conditions associated with metabolic disorders expand the need for effective treatment approaches. Growing attention to early diagnosis and disease progression is encouraging investment in therapeutic development and patient management strategies. The increasing focus on targeted interventions for metabolic liver disease is consequently supporting stronger momentum for the NAFLD segment.
Product Segment Analysis: Antiviral Drugs (Largest Segment) vs Targeted Therapy (Fastest-Growing Segment)
Antiviral drugs held the largest share of the liver disease therapeutics market, accounting for 42.23% in 2026. Their established role in treating viral causes of liver disease supports broad clinical utilization, particularly where suppressing or eliminating viral activity is central to disease management. Continued demand for effective infection control and therapies that can reduce the risk of disease progression sustains the importance of antiviral treatments within the product landscape.
Targeted therapy is gaining momentum as liver disease treatment increasingly moves toward more individualized therapeutic strategies. Targeted approaches are designed to address specific biological pathways or disease characteristics, potentially improving treatment precision and supporting more tailored patient management. Advances in disease understanding and growing emphasis on personalized medicine are encouraging greater development and adoption of targeted therapeutic options.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Disease | Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, Others | Hepatitis | Non-alcoholic Fatty Liver Disease (NAFLD) |
| Product | Antiviral Drugs, Vaccines, Chemotherapy, Targeted Therapy, Immunosuppressants, Immunoglobulins, Corticosteroids, Others | Antiviral Drugs | Targeted Therapy |
Competitive Landscape and Market Positioning
Prominent players in the liver disease therapeutics market:
1. Gilead Sciences Inc. (United States)
2. AbbVie Inc. (United States)
3. Bristol-Myers Squibb Company (United States)
4. F. Hoffmann-La Roche Ltd. (Switzerland)
5. Takeda Pharmaceutical Company Limited (Japan)
6. Johnson & Johnson (United States)
7. Merck & Co. Inc. (United States)
8. Novartis AG (Switzerland)
9. Pfizer Inc. (United States)
10. Sanofi S.A. (France)
The liver disease therapeutics market is progressing through advancements in hepatology-focused research. Development is centered on improving treatment efficacy across chronic liver conditions. The liver disease therapeutics market is also influenced by expanding therapeutic pipeline diversity. Innovation is enhancing disease management strategies.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc. (United States) | |||||||
| AbbVie Inc. (United States) | |||||||
| Bristol-Myers Squibb Company (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Takeda Pharmaceutical Company Limited (Japan) | |||||||
| Johnson & Johnson (United States) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| Novartis AG (Switzerland) | |||||||
| Pfizer Inc. (United States) | |||||||
| Sanofi S.A. (France). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| GSK | May-25 | GSK acquired efimosfermin from Boston Pharmaceuticals for approximately USD 1.2 billion, strengthening its liver disease pipeline with a novel FGF21 analog targeting metabolic liver conditions. The acquisition enhances GSK’s strategic position in emerging non-alcoholic and metabolic liver disease therapeutics through expanded clinical-stage asset ownership. |
| Gilead Sciences, Inc. | Apr-25 | Gilead Sciences presented more than 40 abstracts at the AASLD Liver Meeting covering viral hepatitis, primary biliary cholangitis, and HBV combination therapies. Key data included results from RESPONSE and ASSURE studies on seladelpar and MYR301 data on bulevirtide, reinforcing its clinical leadership across multiple liver disease segments. |
| Takeda Pharmaceutical Company Limited | Mar-25 | Takeda received regulatory approval from Japan’s Ministry of Health, Labour and Welfare for Livmarli oral solution to treat Alagille syndrome and progressive familial intrahepatic cholestasis. The approval strengthens Takeda’s focus on rare pediatric liver diseases with high unmet clinical need. |
| Gilead Sciences, Inc. | Aug-24 | Gilead Sciences received U.S. FDA approval for seladelpar (Pivlaz) for primary biliary cholangitis following positive Phase 3 ENHANCE trial results. The approval followed its USD 4.3 billion acquisition of CymaBay Therapeutics, reinforcing Gilead’s strategy to expand its liver disease portfolio through late-stage clinical assets. |
| Bausch Health | May-24 | Bausch Health completed the acquisition of DURECT Corporation for USD 63 million, gaining access to larsucosterol for alcoholic hepatitis treatment. The asset includes FDA Breakthrough Therapy Designation and represents a potential USD 413 million milestone-linked opportunity, expanding Bausch Health’s presence in liver disease therapeutics focused on advanced hepatic conditions. |
| Boehringer Ingelheim | Apr-24 | Boehringer Ingelheim entered a partnership with Ochre Bio valued at over USD 1 billion to develop regenerative RNA-based therapies for advanced liver disease. The collaboration focuses on deep phenotyping and liver regeneration approaches aimed at addressing unmet needs in severe hepatic conditions through next-generation molecular treatment strategies. |
| Boehringer Ingelheim | Jan-24 | Boehringer Ingelheim partnered with Suzhou Ribo Life Science in a collaboration potentially exceeding USD 2 billion to develop RNA interference therapeutics targeting non-alcoholic steatohepatitis (NASH). The agreement focuses on gene-silencing approaches in hepatocytes to address underlying disease mechanisms in metabolic liver disorders. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Liver Disease Therapeutics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Treatment Stage | First-Line Therapy, Second-Line Therapy, Third-Line and Later-Line Therapy, Maintenance Therapy |
| Route of Administration | Oral, Intravenous, Subcutaneous, Other Parenteral Routes |
| Care Setting | Hospitals, Specialty Clinics, Physician Offices, Home Care |
Liver Disease Therapeutics Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Unmet Clinical Need Assessment |
|
| Treatment Pipeline Opportunity Mapping |
|
| Biomarker and Precision Medicine Adoption Trends |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the liver disease therapeutics market generate?
What is the projected value of the liver disease therapeutics industry by 2036?
How is rising prevalence of NAFLD, hepatitis, and ALD reshaping treatment pathways in the liver disease therapeutics market?
How are antiviral and mRNA-based therapy advancements influencing treatment adoption in the liver disease therapeutics market?
Why are antiviral drugs the largest product segment in the liver disease therapeutics market?
Why is Non-alcoholic Fatty Liver Disease (NAFLD) the fastest-growing disease segment in the liver disease therapeutics market?
Why is North America the leading market for liver disease therapeutics?
What is driving liver disease therapeutics market growth in Asia Pacific?
What are the prominent companies operating in the liver disease therapeutics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization